$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

$vrtx Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000087532018000014 Filed on April 27, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$640.8M	$714.7M
YoY Change	-10.34%	79.54%
Cost Of Revenue	$71.61M	$46.99M
YoY Change	52.41%	-5.63%
Gross Profit	$569.2M	$667.7M
YoY Change	-14.76%	91.72%
Gross Profit Margin	88.82%	93.43%
Selling, General & Admin	$129.8M	$113.3M
YoY Change	14.54%	7.71%
% of Gross Profit	22.81%	16.97%
Research & Development	$310.6M	$273.6M
YoY Change	13.52%	6.92%
% of Gross Profit	54.56%	40.97%
Depreciation & Amortization	$16.34M	$14.85M
YoY Change	10.05%	-9.53%
% of Gross Profit	2.87%	2.22%
Operating Expenses	$440.4M	$386.9M
YoY Change	13.82%	7.15%
Operating Profit	$128.9M	$270.8M
YoY Change	-52.41%	-1990.03%
Interest Expense	$16.89M	-$16.77M
YoY Change	-200.72%	-19.0%
% of Operating Profit	13.1%	-6.19%
Other Income/Expense, Net	$96.84M	-$544.0K
YoY Change	-17901.1%	-112.33%
Pretax Income	$214.6M	$253.5M
YoY Change	-15.34%	-928.08%
Income Tax	-$12.66M	$3.985M
% Of Pretax Income	-5.9%	1.57%
Net Earnings	$210.3M	$247.8M
YoY Change	-15.13%	-695.12%
Net Earnings / Revenue	32.81%	34.66%
Basic Earnings Per Share	$0.83	$1.01
Diluted Earnings Per Share	$0.81	$0.99
COMMON SHARES
Basic Shares Outstanding	253.2M shares	246.0M shares
Diluted Shares Outstanding	258.5M shares	248.7M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.477B	$1.409B
YoY Change	75.8%	37.33%
Cash & Equivalents	$1.996B	$1.004B
Short-Term Investments	$481.0M	$405.0M
Other Short-Term Assets	$119.0M	$173.0M
YoY Change	-31.21%	31.06%
Inventory	$111.7M	$82.02M
Prepaid Expenses
Receivables	$311.2M	$208.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.041B	$1.872B
YoY Change	62.47%	33.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$800.7M	$708.4M
YoY Change	13.03%	2.59%
Goodwill	$50.40M	$50.38M
YoY Change	0.03%	0.0%
Intangibles
YoY Change
Long-Term Investments		$20.00M
YoY Change		-33.33%
Other Assets	$31.80M	$11.49M
YoY Change	176.7%	51.24%
Total Long-Term Assets	$517.5M	$1.075B
YoY Change	-51.85%	-0.94%
TOTAL ASSETS
Total Short-Term Assets	$3.041B	$1.872B
Total Long-Term Assets	$517.5M	$1.075B
Total Assets	$3.559B	$2.947B
YoY Change	20.77%	18.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$74.06M	$63.15M
YoY Change	17.29%	-16.05%
Accrued Expenses	$452.5M	$278.0M
YoY Change	62.81%	1.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$17.00M	$19.00M
YoY Change	-10.53%	-88.41%
Total Short-Term Liabilities	$827.3M	$489.8M
YoY Change	68.91%	-11.28%
LONG-TERM LIABILITIES
Long-Term Debt	$578.0M	$529.0M
YoY Change	9.26%	-19.97%
Other Long-Term Liabilities	$27.46M	$28.47M
YoY Change	-3.53%	-10.54%
Total Long-Term Liabilities	$27.46M	$28.47M
YoY Change	-3.53%	-10.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$827.3M	$489.8M
Total Long-Term Liabilities	$27.46M	$28.47M
Total Liabilities	$1.522B	$1.264B
YoY Change	20.43%	-7.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.111B	-$5.135B
YoY Change	-0.47%	-3.17%
Common Stock	$7.317B	$6.619B
YoY Change	10.54%	5.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.401B	$1.500B
YoY Change
Total Liabilities & Shareholders Equity	$3.559B	$2.947B
YoY Change	20.77%	18.44%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$210.3M	$247.8M
YoY Change	-15.13%	-695.12%
Depreciation, Depletion And Amortization	$16.34M	$14.85M
YoY Change	10.05%	-9.53%
Cash From Operating Activities	$252.7M	$265.7M
YoY Change	-4.91%	-1855.25%
INVESTING ACTIVITIES
Capital Expenditures	$29.28M	$11.10M
YoY Change	163.8%	-7.31%
Acquisitions
YoY Change
Other Investing Activities	$34.20M	-$60.00K
YoY Change	-57100.0%	-25.0%
Cash From Investing Activities	$4.933M	-$161.0M
YoY Change	-103.06%	56.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$10.00M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$78.96M	-$289.6M
YoY Change	-127.27%	-6258.34%
NET CHANGE
Cash From Operating Activities	$252.7M	$265.7M
Cash From Investing Activities	$4.933M	-$161.0M
Cash From Financing Activities	$78.96M	-$289.6M
Net Change In Cash	$338.2M	-$183.5M
YoY Change	-284.34%	62.15%
FREE CASH FLOW
Cash From Operating Activities	$252.7M	$265.7M
Capital Expenditures	$29.28M	$11.10M
Free Cash Flow	$223.4M	$254.6M
YoY Change	-12.26%	-1039.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000875320
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	254830232	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	VERTEX PHARMACEUTICALS INC / MA
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	73994000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	74062000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	281343000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	327294000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	311224000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	443961000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	411231000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	452547000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11572000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-39743000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10623000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7157362000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7314369000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	69790000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	78601000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	69439000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	78136000	USD
CY2018Q1	us-gaap	Amount Of Ineffectiveness On Net Investment Hedges AmountOfIneffectivenessOnNetInvestmentHedges	0	USD
CY2017Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1946000	USD
CY2018Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q4	us-gaap	Assets Assets	3546014000	USD
CY2018Q1	us-gaap	Assets Assets	3952974000	USD
CY2018Q1	us-gaap	Assets Assets	3558639000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	124144000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	2648963000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	3041116000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	594000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1054000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1034013000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1277913000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1108240000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1465716000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	31608000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	594000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1054000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1077226000	USD
CY2018Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1342626000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1033419000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1276859000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	0	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	0	USD
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	22531000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	16919000	USD
CY2017Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	20496000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	16911000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1183945000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1003679000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1665412000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1995893000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1231707000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1048243000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1667526000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2005728000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-183464000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	338202000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	253253362	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	254934949	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	253253362	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	254867865	shares
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1654000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	14637000	USD
CY2018Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2017Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	232401000	USD
CY2018Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	268446000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	2512000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	2541000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	242608000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	206212000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1792000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	17038000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	244400000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	223250000	USD
CY2018Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	225128000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	46988000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	71613000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	443876000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	511898000	USD
CY2016Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2017Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	9229000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1600000000	USD
CY2018Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	204700000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6341000	USD
CY2018Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	9636000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14850000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16343000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.83
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.81
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1388000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1656000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	351000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	465000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	50384000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	50400000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	50384000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	50400000	USD
CY2017Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2018Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	253533000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	214642000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3985000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12700000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12659000	USD
CY2018Q1	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	6400000	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1164000	USD
CY2018Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1897000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	717000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2154000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7798000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13473000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-10465000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7347000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7894000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8208000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1212000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	3587000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	44498000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-25482000	USD
CY2018Q1	us-gaap	Increase In Unrecognized Tax Benefits Is Reasonably Possible IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	0	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	12000	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	34000	shares
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-16765000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-11097000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	17527000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	16825000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16669000	USD
CY2018Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	21527000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	111830000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	117346000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	111740000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20924000	USD
CY2018Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17587000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	74237000	USD
CY2018Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	78232000	USD
CY2017Q1	us-gaap	Inventory Write Down InventoryWriteDown	3787000	USD
CY2018Q1	us-gaap	Inventory Write Down InventoryWriteDown	3619000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	1503708000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	1522153000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3546014000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3952974000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3558639000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	807260000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	827312000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	423254000	USD
CY2018Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	481124000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	13727000	USD
CY2018Q1	us-gaap	Minority Interest MinorityInterest	29765000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-289565000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78956000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-160979000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4933000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	265692000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	252657000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	247756000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	210263000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1792000	USD
CY2018Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17038000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	247350000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	210164000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	247355000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	210166000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	12549000	USD
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	3716000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	270842000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	128901000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28230000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31804000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1269000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-10828000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2001000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2729000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5148000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4051000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	248273000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	38653000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	21500000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-6681000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-862000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	900000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27774000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27462000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	300000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5152000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-5827000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-544000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	96838000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	10000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3534000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-460000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2017Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	29000000	USD
CY2018Q1	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	29000000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	34373000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	56654000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	36456000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11099000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29279000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	165635000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	109886000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	148469000	USD
CY2017Q1	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable	0	USD
CY2018Q1	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable	9566000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11249000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	88403000	USD
CY2016Q4	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	300000000	USD
CY2017Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-117000	USD
CY2018Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1134000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	98393000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94365000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	249548000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	227301000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	789437000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	800670000	USD
CY2017Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	3879000	USD
CY2018Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-6777000	USD
CY2017Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	300000000	USD
CY2018Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	4703000	USD
CY2018Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9197000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	273563000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	310553000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	47762000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	44564000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1489000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	9573000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	9999000	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	-76000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5119723000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4876111000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5111443000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	714718000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	640799000	USD
CY2017Q1	us-gaap	Revenues Revenues	714718000	USD
CY2018Q1	us-gaap	Revenues Revenues	640799000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1551000	USD
CY2018Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1356000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	480622000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	637729000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113326000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	129808000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	69439000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	78136000	USD
CY2018Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	4738000	shares
CY2018Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	9955000	shares
CY2018Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	84.36
CY2018Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	103.03
CY2018Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2017Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	31028000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	89686000	USD
CY2018Q1	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	500000000.0	shares
CY2018Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	67084	shares
CY2018Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11300000	USD
CY2018Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	11251000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2028579000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	2401056000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1338191000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1682793000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2042306000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2430821000	USD
CY2017Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	616000	USD
CY2018Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	1000000	USD
CY2017Q1	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	-401000	USD
CY2018Q1	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	-97000	USD
CY2017Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	406000	USD
CY2018Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	99000	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	95500000	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	0	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Securities UnrealizedGainLossOnSecurities	95458000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3800000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4800000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	248700000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	258526000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	246024000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	253231000	shares
CY2017Q4	vrtx	Advanced Funding Received From Collaborator AdvancedFundingReceivedFromCollaborator	78431000	USD
CY2018Q1	vrtx	Advanced Funding Received From Collaborator AdvancedFundingReceivedFromCollaborator	79537000	USD
CY2017Q1	vrtx	Collaborative Revenues CollaborativeRevenues	232545000	USD
CY2018Q1	vrtx	Collaborative Revenues CollaborativeRevenues	1714000	USD
CY2017Q4	vrtx	Construction Financing Obligation Noncurrent ConstructionFinancingObligationNoncurrent	563406000	USD
CY2018Q1	vrtx	Construction Financing Obligation Noncurrent ConstructionFinancingObligationNoncurrent	561295000	USD
CY2017Q4	vrtx	Contingent Liabilities ContingentLiabilities	0	USD
CY2018Q1	vrtx	Contingent Liabilities ContingentLiabilities	0	USD
CY2018Q1	vrtx	Contractwith Customer Liability Additions ContractwithCustomerLiabilityAdditions	12983000	USD
CY2018Q1	vrtx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	21900000	USD
CY2017Q1	vrtx	Employee Benefit Plan Payable Receivable EmployeeBenefitPlanPayableReceivable	19847000	USD
CY2018Q1	vrtx	Employee Benefit Plan Payable Receivable EmployeeBenefitPlanPayableReceivable	2124000	USD
CY2018Q1	vrtx	Indemnification Claims IndemnificationClaims	0	USD
CY2016Q4	vrtx	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	300000000.0	USD
CY2017Q1	vrtx	Proceeds From Collaborative Funding ProceedsFromCollaborativeFunding	5000000	USD
CY2018Q1	vrtx	Proceeds From Collaborative Funding ProceedsFromCollaborativeFunding	2500000	USD
CY2017Q1	vrtx	Repaymentsof Collaborative Funding RepaymentsofCollaborativeFunding	994000	USD
CY2018Q1	vrtx	Repaymentsof Collaborative Funding RepaymentsofCollaborativeFunding	1182000	USD
CY2018Q1	vrtx	Revenue From Contract With Customer Credits Percentageof Gross Revenue RevenueFromContractWithCustomerCreditsPercentageofGrossRevenue	0.01
CY2018Q1	vrtx	Revenue From Contract With Customer Payment Term RevenueFromContractWithCustomerPaymentTerm	P30D
CY2018Q1	vrtx	Stock Repurchase Program Accrued Liabilities StockRepurchaseProgramAccruedLiabilities	1300000	USD
CY2018Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivatives and Hedging</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, the FASB issued ASU 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815) </font><font style="font-family:inherit;font-size:10pt;">(“ASU 2017-09”). ASU 2017-09 helps simplify certain aspects of hedge accounting and enables entities to more accurately present their risk management activities in their financial statements. The new guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted. The Company is in the process of determining the expected effect on its condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leasing</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (“ASU 2016-02”). ASU 2016-02 is applicable to leases that will be effective for the year ending December 31, 2019. Early adoption is permitted. ASU 2016-02 requires entities to recognize assets and liabilities for leases with lease terms of more than 12 months on the balance sheet and requires a modified-retrospective adoption approach. The Company is in the process of evaluating this guidance and determining the expected effect on its condensed consolidated financial statements; however, it anticipates that the amended guidance will result in the Company recording additional assets and corresponding liabilities on its condensed consolidated balance sheets. The Company has formed a project team to review its portfolio of existing leases and current accounting policies to identify and assess the potential differences that would result from applying the requirements of the new standard.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies—Recent Accounting Pronouncements,” in the </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K. </font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation and deconsolidation of VIEs, leases, the fair value of cash flow hedges, deferred tax asset valuation allowances and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div>

Files In Submission

Name	View Source	Status
0000875320-18-000014-index-headers.html	Edgar Link	pending
0000875320-18-000014-index.html	Edgar Link	pending
0000875320-18-000014.txt	Edgar Link	pending
0000875320-18-000014-xbrl.zip	Edgar Link	pending
a2018q110-q.htm	Edgar Link	pending
a2018q110-q_exhibit311.htm	Edgar Link	pending
a2018q110-q_exhibit312.htm	Edgar Link	pending
a2018q110-q_exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrtx-20180331.xml	Edgar Link	completed
vrtx-20180331.xsd	Edgar Link	pending
vrtx-20180331_cal.xml	Edgar Link	unprocessable
vrtx-20180331_def.xml	Edgar Link	unprocessable
vrtx-20180331_lab.xml	Edgar Link	unprocessable
vrtx-20180331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

2018 Q1 Form 10-Q Financial Statement

#000087532018000014 Filed on April 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTX VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

2018 Q1 Form 10-Q Financial Statement

#000087532018000014 Filed on April 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx